1/ Draper wins patent for electrostatic motor - eTransport News
etransportnews.com/2021/04/05/dra…
Draper is developing a family of electric motors and generators based on fundamentally different principles from common e-motors used today.
2/ Draper says its approach to electric motors has numerous advantages over conventional electric motors, including lower weight, higher efficiency, higher specific power and lower cost of materials.

Patent on aspects of the technology:
patents.google.com/patent/US20190…
3/ The company’s patented approach to electric motors, which is available to license, replaces steel, copper coils and rare earth magnets with thin, light and widely available materials.
draper.com/news-releases/…
4/ “Our e-motors use thin electrodes and electrets which reduce weight by 80% or more as compared to conventional motors,” said Manager Sabrina Mansur. “This translates to a range extension of up to 40% for drones and up to 25% for electric vehicles, based on our simulations..."

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Roland Baker

Roland Baker Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @RolandBakerIII

4 Apr
Update from NYT: Department of Health and Human Services has given AstraZeneca the boot from Emergent BioSolutions and will put Johnson & Johnson in full control after a mix-up of the ingredients of their respective vaccines caused a loss of 15M doses.

archive.fo/Ycuf3
"The change came in response to the recent disclosure that Emergent, a manufacturing partner to both AstraZeneca and Johnson & Johnson, accidentally mixed up the ingredients from the two different vaccines, which forced regulators to delay authorization of the plant’s production"
"Experts in vaccine manufacturing said that in the past, the Food and Drug Administration had a rule to prevent such mishaps by not allowing a facility to make two live viral vector vaccines, because of the potential for mix-ups and contamination."
Read 4 tweets
3 Apr
@Harvard2H You call it a pseudo-vaccine. Why would we care if it is called a pseudo-vaccine as long as it is safe and effective? I think the reasoning behind attempting a mRNA vaccine was pretty clearly articulated:

Science: Rapid COVID-19 vaccine development
science.sciencemag.org/content/368/64…
@Harvard2H Indeed prior to the testing of mRNA vaccines for COVID-19 a total of nine different mRNA vaccines had already been in human trials.
@Harvard2H And the mRNA vaccines for COVID-19 were certainly tested for efficacy in animals not just in vitro:

mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge
biorxiv.org/content/10.110…
Read 47 tweets
3 Apr
Israeli Study: 1-14 days after the 1st dose of Pfizer there was a 30% reduction in COVID-19 (CI 2-50 Note - huge CI), days 15–28 there was a 70% reduction (72-84).

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
thelancet.com/journals/lance…
Note the huge confidence interval on the first dose in the first 14 days. That gives us a clue as to why we see such starkly different results during the first 14 days in various studies. You really can't say with confidence much of anything until after 14 days.
Contrast this research with another study in Isreal:

Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel
medrxiv.org/content/10.110…
Read 14 tweets
21 Mar
(1/n) Fascinating paper examining three neutralizing classes of anti-RBD antibodies and immune escape.

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies: Anti-RBD
biorxiv.org/content/10.110…
(2/n) Class 2 antibodies bind to epitopes proximal to RBD that are exposed in both up and down conformations of the RBD, and are often generated from frequently observed germline genes (​VH1-2​, ​VH3-53​, ​VH1-69​). These are responsible for most immune escape mutations (E484)
(3/n) Class 1 antibodies can only bind to the RDB in the up confirmation, mutations like K417N/T results in escape. Class 3 do not directly bind to the ACE2 contact surface but are still neutralizing and mutations like L452R result in immune escape.
Read 6 tweets
20 Mar
Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin: nucleocapsid protein (NP) of SARS-CoV-2 significantly activated human endothelial cells through TLR2/NF-κB and MAPK signaling pathways.
pubmed.ncbi.nlm.nih.gov/33594363/
"To confirm the specific inhibitory role of simvastatin in N protein-induced endothelial activation, we compared the effect of simvastatin, lovastatin, atorvastatin, mevastatin and rosuvastatin. As shown in Fig.5a, among the five statins tested, simvastatin potently inhibited
N protein-induced expression of ICAM-1 and VCAM-1. Consistent with the screening results, lovastatin showed mild effect on N protein-induced endothelial activation. The other three statins did not affect N protein-induced endothelial activation."
Read 8 tweets
18 Mar
Live Video! European Medicines Agency press conference: AstraZeneca Safety
EMA: AstraZeneca - clear scientific conclusion that this is a safe and effective vaccine and not associated with risk thrombotic events. Will make public aware of rare risks. 7 million EU people vaccinated and 11 million in UK. At least 60% effective against Coronavirus disease.
EMA: The situation of rare illness is not unexpected following vaccination and the EMA is investigating these adverse reactions. Will raise awareness and present updated information.
Read 14 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!